Polycythemia Vera Clinical Trial
Official title:
Molecular Biology of Familial Myeloproliferative Disorders
Verified date | September 2017 |
Source | Icahn School of Medicine at Mount Sinai |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Myeloproliferative disorders occur in families, thus giving rise to the theory that it is a genetic disease that may be caused by an abnormal gene in the DNA that can be passed from one generation of family members to another. DNA can be gathered from family members through blood samples and the investigators will investigate (through DNA testing) to see if there are abnormal genes that may be responsible for causing the MPDs. Understanding which genes are responsible for causing MPDs can help develop ways to identify people who may be at risk for developing an MPD, allow for the development of better treatments, possibly a cure, or even prevent the development of MPDs.
Status | Completed |
Enrollment | 17 |
Est. completion date | June 20, 2015 |
Est. primary completion date | January 20, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years and older |
Eligibility |
Inclusion Criteria: - Families with 2 or more members diagnosed with polycythemia vera (PV), essential thrombocythemia (ET), PV and ET related myelofibrosis (PV-MF and ET-MF), idiopathic myelofibrosis (IM) or chronic myelogenous leukemia (CML). - Healthy family members of subjects diagnosed with a myeloproliferative neoplasm (MPN). - Participating subjects must be 7 years of age or older - A written assent, parental permission or consent must be obtained prior to any study procedures being performed. Exclusion Criteria: - Subjects who have a known acquired cause of polycythemia (increased hemoglobin/hematocrit), such as people living in high altitudes (in excess of 14,000 feet), subjects with heart disease, left to right heart shunt, severe hypoxia, cyanotic congenital heart disease, or severe pulmonary disease, will be excluded from this study, secondary forms of thrombocytosis and secondary forms of myelofibrosis. |
Country | Name | City | State |
---|---|---|---|
Italy | University of Florence | Florence | |
United States | University of Illinois at Chicago | Chicago | Illinois |
United States | Mount Sinai School of Medicine | New York | New York |
United States | Weill Cornell | New York | New York |
United States | University of Utah | Salt Lake City | Utah |
United States | Georgetown University | Washington, D.C. | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai | Myeloproliferative Disorders-Research Consortium, National Cancer Institute (NCI) |
United States, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine a linkage from the DNA analyzed to find a gene that will allow for genetic evaluation of families with MPDs. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05558696 -
A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)
|
Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Completed |
NCT02912884 -
Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure
|
||
Recruiting |
NCT02897297 -
Myeloproliferative Neoplastic Diseases Observatory From Brest
|
||
Completed |
NCT01949805 -
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
|
Phase 3 | |
Completed |
NCT00666549 -
Research Tissue Bank
|
||
Completed |
NCT00241241 -
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
|
Phase 2 | |
Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05485948 -
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
|
Phase 2 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT01243944 -
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
|
Phase 3 | |
Recruiting |
NCT05481151 -
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
|
Phase 3 | |
Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT04116502 -
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
|
Phase 3 | |
Completed |
NCT01901432 -
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04262141 -
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
|
Phase 2 | |
Not yet recruiting |
NCT05566535 -
Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice
|
||
Active, not recruiting |
NCT04057040 -
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
|
Phase 2 | |
Completed |
NCT03907436 -
The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase
|
N/A | |
Completed |
NCT01981850 -
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
|
Phase 2 |